GKOS

Glaukos Licenses Iveena’s Investigational Keratoconus Therapy

Retrieved on: 
Wednesday, August 24, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Optical, Technology, NYSE, Retina, Cornea, Glaucoma, GKOS, ODD, LOX, Myopia, MIGS, Keratoconus, Glaucoma surgery, Clinical trial, Trial of the century, Patient, Pharmaceutical industry

iVeena Delivery Systems Inc. (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus.

Key Points: 
  • iVeena Delivery Systems Inc. (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus.
  • Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States.
  • Glaukos is a strong partner to complete development of this product where, if approved, patients will have an additional keratoconus treatment option.
  • iVeena has licensed its lead asset to Glaukos Corporation, IVMED-80, an Orphan Drug Designated eye drop for keratoconus.

Glaukos Announces FDA 510(k) Clearance of iStent infinite®

Retrieved on: 
Wednesday, August 3, 2022
FDA, Optical, Health, Medical Devices, Corporation, Security (finance), GKOS, Retina, Glaucoma, NYSE, Food, Patient, U.S. Securities and Exchange Commission, Humour, FDA, Adult, MIGS, Regulation of tobacco by the U.S. Food and Drug Administration, IOP, Stent, Glaucoma surgery, Clinical trial, SEC, Pharmaceutical industry

The iStent infinite has a similar mechanism of action to the companys two-stent iStent inject W Trabecular Micro-Bypass System, which is approved by the FDA for the reduction of IOP in adult mild-to-moderate primary open-angle glaucoma patients undergoing concomitant cataract surgery.

Key Points: 
  • The iStent infinite has a similar mechanism of action to the companys two-stent iStent inject W Trabecular Micro-Bypass System, which is approved by the FDA for the reduction of IOP in adult mild-to-moderate primary open-angle glaucoma patients undergoing concomitant cataract surgery.
  • This FDA clearance for iStent infinite represents a significant milestone for Glaukos and the MIGS market as the first FDA-cleared micro-invasive implantable device indicated for use as a standalone treatment option for glaucoma patients not undergoing concomitant cataract surgery, said Thomas Burns, chairman and chief executive officer.
  • We are grateful to the clinical investigators and patients who participated in the clinical trial for their instrumental roles in helping us reach this pioneering achievement and bring iStent infinite to the U.S.
  • The company intends to commence initial commercial launch activities for iStent infinite later this year.

Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3

Retrieved on: 
Wednesday, July 13, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Optical, Glaucoma, Conference, Glaucoma surgery, Corporation, MIGS, NYSE, GKOS, International, Retina, Pharmaceutical industry

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022.
  • The companys management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m.
  • To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Glaukos Announces Participation in the William Blair Growth Stock Conference

Retrieved on: 
Thursday, June 2, 2022
Health, Medical Devices, Infectious Diseases, Technology, Surgery, Other Technology, Pharmaceutical, GKOS, Glaucoma surgery, Corporation, Glaucoma, Conference, NYSE, Retina, MIGS, Pharmaceutical industry

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 42nd Annual Growth Stock Conference on Wednesday, June 8, 2022, at 8:40 a.m. CT in Chicago, IL.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 42nd Annual Growth Stock Conference on Wednesday, June 8, 2022, at 8:40 a.m. CT in Chicago, IL.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and has since developed a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations.
  • Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

Chau Khuong Joins Catalio Capital Management as General Partner

Retrieved on: 
Wednesday, May 25, 2022
Professional Services, Health, Medical Devices, Finance, Consulting, Pharmaceutical, Biotechnology, Nexus, INSP, General partnership, Biomedical technology, Partnership, Board, Investment, NASDAQ, Initial public offering, GKOS, Research, FDA, Partner, Oaktree Capital Management, Roche, NTLA, Intercept Pharmaceuticals, Senior advisor, Yale University, Acquisition, Entrepreneurship, Equal Credit Opportunity Act, NYSE, Sequah Medicine Company, Pharmaceutical industry, LP, Pfizer

Catalio Capital Management, LP (Catalio), a leading multi-strategy life sciences investment firm, today announced that Chau Khuong, who was most recently a Partner at OrbiMed Advisors, has joined the firm as General Partner and Senior Advisor.

Key Points: 
  • Catalio Capital Management, LP (Catalio), a leading multi-strategy life sciences investment firm, today announced that Chau Khuong, who was most recently a Partner at OrbiMed Advisors, has joined the firm as General Partner and Senior Advisor.
  • Throughout his career, Mr. Khuong has led or co-led investments in over two dozen life science companies, resulting ultimately in twelve FDA approved medicines or therapeutic devices.
  • Co-Founder and Managing Partner George Petrocheilos said, At Catalio, we are building a highly differentiated portfolio of industry-leading companies led by the brightest minds in the life sciences space.
  • Catalio Capital Management, LP, is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights.

Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium

Retrieved on: 
Friday, May 20, 2022
Health, Optical, Surgery, Glaucoma, Glaucoma surgery, Corporation, MIGS, Ophthalmology, GKOS, NYSE, Retina, Pharmaceutical industry

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Piper Sandler Ophthalmology Symposium on Monday, May 23, 2022, at 2:00 p.m.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Piper Sandler Ophthalmology Symposium on Monday, May 23, 2022, at 2:00 p.m.
  • ET.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

Glaukos Corporation Announces First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022
General Health, Optical, Health, Medical Devices, COVID-19, MIGS, U.S. Securities and Exchange Commission, Glaucoma, Standard of care, Income, Investment, Communication, GKOS, GAAP, ASC, Company, NYSE, Research, Corporation, Patient, Security (finance), Webcast, Acquisition, Clinical trial, Retina, SG, Annual report, Industry, Patent, Investor relations, Compliance, CMS, R, Ivanti, Marketing, Sale, Conference, SEC, Glaucoma surgery, Risk, Seven Group Holdings, Cornea, Pharmaceutical industry, Beauty salon, Lithium, Risk management

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2022.
  • Net sales in the first quarter of 2022 were $67.7 million, compared to $68.0 million in the same period in 2021.
  • Gross margin for the first quarter of 2022 was approximately 75%, compared to approximately 76% in the same period in 2021.
  • To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures.

Glaukos Announces the Release of its 2021 Sustainability Report

Retrieved on: 
Wednesday, April 20, 2022
Pharmaceutical, Health, Optical, U.S. Securities and Exchange Commission, ISO, Security (finance), Annual report, GKOS, Glaucoma surgery, Sustainability reporting, ESG, Goal, Patient, DEI, Corporation, Glaucoma, Sustainability, NYSE, Certification, MIGS, Time, Retina, Pharmaceutical industry, Risk management, 1870 Glaukos

I am proud to issue our third annual Sustainability Report reflecting our commitment to continuous improvement as responsible corporate citizens, said Thomas Burns, Glaukos chairman and chief executive officer.

Key Points: 
  • I am proud to issue our third annual Sustainability Report reflecting our commitment to continuous improvement as responsible corporate citizens, said Thomas Burns, Glaukos chairman and chief executive officer.
  • Over the course of 2021, we continued to invest significant time and resources into better understanding what drives sustainability at Glaukos.
  • For additional information and highlights, please see Glaukos 2021 Sustainability Report, which can be found on the companys website here .
  • These potential risks and uncertainties include, without limitation, our ability to achieve the sustainability targets identified in the sustainability report.

Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4

Retrieved on: 
Wednesday, April 13, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Optical, NYSE, Conference, Corporation, International, Glaucoma, GKOS, Glaucoma surgery, MIGS, Retina, Pharmaceutical industry

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2022 financial results after the market close on Wednesday, May 4, 2022.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2022 financial results after the market close on Wednesday, May 4, 2022.
  • The companys management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m.
  • To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy

Retrieved on: 
Monday, March 14, 2022
Medical Devices, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Safety, Cornea, GKOS, Keratoconus, U.S. Securities and Exchange Commission, IEEE, Annual report, Corneal cross-linking, Glaucoma surgery, Retina, NYSE, Patient, Security (finance), Glaucoma, MIGS, Corporation, SEC, Pharmaceutical industry

Glaukos third-generation iLink therapy is a corneal cross-linking treatment designed to customize the therapeutic capabilities, streamline the patient experience and build upon Glaukos first-generation iLink therapy, known as iLink Epi-off, and its second-generation iLink investigational therapy, known as iLink Epi-on.

Key Points: 
  • Glaukos third-generation iLink therapy is a corneal cross-linking treatment designed to customize the therapeutic capabilities, streamline the patient experience and build upon Glaukos first-generation iLink therapy, known as iLink Epi-off, and its second-generation iLink investigational therapy, known as iLink Epi-on.
  • As we do with all of our platforms, we continue to drive subsequent generations of future innovation, and we are delighted to announce the commencement of this Phase 2 clinical program for our third-generation iLink therapy, said Thomas Burns, Glaukos president and chief executive officer.
  • Our third-generation iLink therapy builds upon our proven iLink platform therapies and we are delighted to have the opportunity to explore what this promising investigational therapy can do for keratoconus patients in our Phase 2 trials.
  • The third-generation iLink Phase 2 clinical program consists of two separate multi-center, randomized, controlled trials designed to evaluate the safety and efficacy of patient-specific, customized versus non-customized treatment patterns for corneal cross-linking and a new investigational laser-based bio-activation system, respectively.